Merck & (MRK) – Analysts’ Recent Ratings Changes

Merck & (NYSE: MRK) has recently received a number of price target changes and ratings updates:

  • 11/15/2017 – Merck & had its “buy” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $64.00 price target on the stock.
  • 11/3/2017 – Merck & had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $70.00 price target on the stock.
  • 11/1/2017 – Merck & was downgraded by analysts at Jefferies Group LLC from a “hold” rating to an “underperform” rating.
  • 11/1/2017 – Merck & had its “hold” rating reaffirmed by analysts at Berenberg Bank.
  • 10/31/2017 – Merck & was upgraded by analysts at Jefferies Group LLC from an “underperform” rating to a “hold” rating. They now have a $48.00 price target on the stock, down previously from $54.41.
  • 10/30/2017 – Merck & was upgraded by analysts at Citigroup Inc. to a “buy” rating.
  • 10/30/2017 – Merck & had its price target lowered by analysts at Leerink Swann from $70.00 to $69.00. They now have a “market perform” rating on the stock.
  • 10/30/2017 – Merck & was given a new $68.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 10/30/2017 – Merck & was downgraded by analysts at Barclays PLC from an “overweight” rating to an “equal weight” rating. They now have a $62.00 price target on the stock, down previously from $72.00.
  • 10/30/2017 – Merck & was downgraded by analysts at SunTrust Banks, Inc. from a “buy” rating to a “hold” rating.
  • 10/30/2017 – Merck & was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $56.00 price target on the stock.
  • 10/30/2017 – Merck & had its price target lowered by analysts at UBS AG from $72.00 to $67.00. They now have a “buy” rating on the stock.
  • 10/29/2017 – Merck & was given a new $70.00 price target on by analysts at J P Morgan Chase & Co. They now have a “buy” rating on the stock.
  • 10/23/2017 – Merck & had its price target raised by analysts at Leerink Swann from $69.00 to $70.00. They now have a “market perform” rating on the stock.
  • 10/20/2017 – Merck & had its “sell” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $55.00 price target on the stock.
  • 10/18/2017 – Merck & was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $72.00 price target on the stock.
  • 10/18/2017 – Merck & was given a new $70.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 10/17/2017 – Merck & was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Merck has made significant progress with its pipeline and is working on bringing new products to the market. New products like Keytruda and Zepatier should continue to contribute meaningfully to sales. Keytruda is gaining strong momentum from new indication of first-line lung cancer. The Keytruda development program also significantly advanced in the first half with several key regulatory approvals. Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competition in the immuno-oncology market is also a significant concern. Merck’s shares underperformed the industry this year so far. Estimates have declined slightly ahead of the company’s Q3 earnings release. Merck has a positive record of earnings surprises in the recent quarters.”
  • 10/12/2017 – Merck & had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $72.00 price target on the stock.
  • 10/11/2017 – Merck & was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Merck’s new products like Keytruda and Zepatier should continue to contribute meaningfully to the top line. However, generic competition for several drugs will continue to be overhangs on the top line. Competitive and pricing pressures are also hurting sales of drugs like Isentress and Remicade. The diabetes franchise is also seeing slow sales since the past few quarters. Rising competition in the immuno-oncology market is also a significant concern. Meanwhile, Merck has also had its share of pipeline and regulatory setbacks. It recently dropped development of two of its HCV programs as the HCV market is becoming extremely crowded. Merck’s shares underperformed the industry this year so far. Estimates have remained stable ahead of the company’s Q3 earnings release. Merck has a positive record of earnings surprises in the recent quarters.”
  • 10/11/2017 – Merck & was given a new $70.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.

Merck & Company, Inc. (MRK) traded down $0.19 during trading hours on Thursday, reaching $54.80. The company’s stock had a trading volume of 11,727,400 shares, compared to its average volume of 9,536,841. Merck & Company, Inc. has a twelve month low of $54.40 and a twelve month high of $66.80. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $150,630.00, a price-to-earnings ratio of 14.14, a PEG ratio of 2.37 and a beta of 0.78.

Merck & (NYSE:MRK) last released its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The business had revenue of $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. During the same quarter in the previous year, the company posted $1.07 earnings per share. Merck &’s revenue for the quarter was down 2.0% on a year-over-year basis. equities analysts anticipate that Merck & Company, Inc. will post 3.95 earnings per share for the current year.

In other news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.25% of the company’s stock.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Receive News & Ratings for Merck & Company Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply